Immunotherapy

Program Goals

Innate and Adaptive Immunity

Tumor Cells Are Not "Self"

Two Signals for T-Cell Activation

Receptors Control T Cell Function

Immunity in Tumor Control

Tumor Control: Immune Cell Deactivation

Immunotherapy Strategies

Incidence of ALL

ALL: Outcomes in Adults and Children

B Cell Surface Antigens

Blinatumomab Clinical Results

Toxicities of Special Interest in Patients Treated With Blinatumomab

Toxicities With Blinatumomab

Revised CRS Grading System

Overall Survival in Pediatric Blinatumomab Trial*

Immune-Checkpoint Axis: Maintains Self-Tolerance and Prevents Autoimmunity

PD-1/PD-L1 Pathway Signaling

PD-1/PD-L1 Pathway

PD-1/PD-L1 in the Immune Response

Pathogenesis of Hodgkin Lymphoma

Ongoing Clinical Trials in Hematologic Malignancies

Nivolumab in HL

Pembrolizumab in cHL After BV Failure (KEYNOTE-013)

KEYNOTE-013: Tumor Size Change From Baseline

Summary and Questions